MK-2206 for Recurrent Malignant Glioma

NCT01249105 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
OTHER
Sponsor class

Stopped Merck (supplier of study drug \& funding) has undergone a large reprioritization, in which they had to terminate many oncology trials, including this one.

Conditions

Interventions

Sponsor

Dana-Farber Cancer Institute

Collaborators